

10/019833

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 October 2000 (26.10.2000)

PCT

(10) International Publication Number
WO 00/62795 A3

(51) International Patent Classification⁷: A61K 38/17, G01N 33/50, 33/68, C12Q 1/68, A61P 31/12, 29/00, 11/00 // A01K 67/00, C07K 14/47, C12N 15/12, (A61K 38/17, 31:56)

(21) International Application Number: PCT/US00/09979

(22) International Filing Date: 13 April 2000 (13.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/130,434 21 April 1999 (21.04.1999) US

(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES The National Institutes of Health [US/US]; Office of Technology Transfer, 6011 Executive Boulevard Suite 325, Rockville, MD 20852 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MUKHERJEE, Anil, B. [US/US]; P.O. Box 136, Brookeville, MD 20833 (US). ZHENG, Feng [US/US]; 10 Chantilly Court, Rockville, MD 20850 (US). ZHANG, Zhongjian [US/US]; 10 Chantilly Court, Rockville, MD 20850 (US).

(74) Agent: NOONAN, William, D.; Klarquist, Sparkman, Campbell, Leigh & Winston, LLP, One World Trade Center, Suite 1600, 121 S.W. Salmon Street, Portland, OR 97204 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report: 13 September 2001

(48) Date of publication of this corrected version: 4 October 2001

(15) Information about Correction:

see PCT Gazette No. 40/2001 of 4 October 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/62795 A3

(54) Title: UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS

(57) Abstract: Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals, and animals in which uteroglobin-protein expression is reduced by antisense technology, also provide systems for studying IgA mediated diseases, and screening for appropriate treatments.